Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2025)

Beta Bionics' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $328.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 119.68% year-over-year to $328.7 million; the TTM value through Dec 2025 reached $1.3 billion, up 786.62%, while the annual FY2025 figure was $328.7 million, 119.68% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $328.7 million at Beta Bionics, roughly flat from $330.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $338.0 million in Q1 2025 and bottomed at $110.0 million in Q4 2023.
  • The 3-year median for Liabilities and Shareholders Equity is $329.4 million (2025), against an average of $264.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 35.99% in 2024 before it surged 119.68% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $110.0 million in 2023, then skyrocketed by 35.99% to $149.6 million in 2024, then soared by 119.68% to $328.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Liabilities and Shareholders Equity are $328.7 million (Q4 2025), $330.0 million (Q3 2025), and $330.0 million (Q2 2025).